CytoDyn Inc. (OTCMKTS:CYDY) Short Interest Update

CytoDyn Inc. (OTCMKTS:CYDY) recently saw a notable increase in short interest during January. As of January 31st, the total short interest reached 22,639,300 shares, reflecting a rise of 6.4% compared to the total of 21,272,500 shares as of January 15th. With an average daily trading volume of 11,699,700 shares, the current days-to-cover ratio stands at 1.9 days.

CytoDyn Stock Performance

On Friday, CytoDyn's stock price showed a slight increase of 0.2%, reaching $0.22 during trading hours. A total of 1,991,689 shares were traded, which is less than its average volume of 4,342,034. The company has a market capitalization of $267.36 million, a price-to-earnings ratio of -21.73, and a low beta of 0.01. Over the last year, the stock recorded a low of $0.10 and a high of $0.32, while its 50-day moving average is at $0.16 and its 200-day moving average at $0.15.

About CytoDyn Inc.

CytoDyn Inc. is a clinical-stage biotechnology company dedicated to developing treatments for a range of medical conditions. The firm is primarily focused on the clinical development of leronlimab, a unique humanized monoclonal antibody that targets the C-C chemokine receptor type 5 (CCR5). CytoDyn's research areas include treatments for COVID-19, human immunodeficiency virus (HIV), metabolic dysfunction-associated steatohepatitis (MASH), and various oncology indications such as metastatic triple-negative breast cancer.

Investment Considerations

Before making a decision regarding an investment in CytoDyn, it is advised to review current evaluations and recommendations from leading analysts. Market data indicates that while CytoDyn holds a "Hold" rating among analysts, there are other stocks that are being favored for investment.

CytoDyn, Stocks, Short